Evox has raised more than 35 million pounds for in-body therapy

Oxford-based Evox Therapeutics has raised more than 35 million pounds to advance its exosome-based treatment pipeline.
the company received "significant new investments" from GV (formerly Google Ventures) and Cowen Healthcare Investments in a financing round led by Redmile Group, together with investments from Panacea Healthcare Ventures and Borealis Ventures and a small number of private investors.
existing investors, including Oxford Science Innovation (OSI) and Oxford University, which have injected more than 10m pounds into the company.
Evox is designing exosomes, the body's natural blister delivery systems, to enable a wide variety of drugs to reach previously inoculated tissues and compartments, such as delivering drugs through the blood-brain barrier to the central nervous system, intracellular delivery of biologic agents, and liver delivery of RNA therapies.
is developing its own proprietary pipeline of exosomes to treat rare, life-threatening diseases that are severely under-demand, and partners with major drugs "leverage exosome-based therapies for the treatment of a variety of other diseases." "
this new investment will be used to advance several proprietary rare disease assets to clinics and to further develop an exosome drug platform.
believes that exosomes represent an important emerging treatment with broad applicability, and we are passionate about working with the Evox team," he said. Jeremy Green, founder and portfolio manager at Redmile Group, said. (This net special draft)